Acerand Therapeutics (Hong Kong) Limited
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Acerand Therapeutics (Hong Kong) Limited sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).
Acerand Therapeutics (Hong Kong) Limited: 1 sponsored US clinical trial, 1 recruiting.
Acerand Therapeutics (Hong Kong) Limited sponsors 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is mCRPC (Metastatic Castration-resistant Prostate Cancer), with 1 trials.
Mid-pack sponsor footprint
Acerand Therapeutics (Hong Kong) Limited is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Open and recent trials
1 total, page 1 of 1
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
Therapeutic Areas
What is open in the Acerand Therapeutics (Hong Kong) Limited pipeline
1 recruiting of 1 indexed (100% open).
Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).
Top condition: mCRPC (Metastatic Castration-resistant Prostate Cancer) (1 trial), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Acerand Therapeutics (Hong Kong) Limited: open-pipeline peers nationwide
Peers matched on 1 registered trials and 100% open enrollment, not the therapeutic-area sidebar.
Acerand Therapeutics (Hong Kong) Limited sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1 trials (± recruiting share)
- 1200 Pharma · 2 trials · 50% recruiting
- 1ST Biotherapeutics · 2 trials · 50% recruiting
- 3 Waves Wellness · 2 trials · 0% recruiting
- 3EO Health · 2 trials · 0% recruiting
Sponsors near 100% open enrollment (± trial volume)
- AAVantgarde Bio Srl · 100% recruiting · 2 trials
- Acorn Biolabs · 100% recruiting · 3 trials
- Acrivon Therapeutics · 100% recruiting · 2 trials
- ADARx Pharmaceuticals · 100% recruiting · 4 trials
Related
What to do with this Acerand Therapeutics (Hong Kong) Limited page
1 registered trials is a research-attention snapshot, not an endorsement of Acerand Therapeutics (Hong Kong) Limited or any single study.
- 1 of Acerand Therapeutics (Hong Kong) Limited's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- mCRPC (Metastatic Castration-resistant Prostate Cancer) is the condition Acerand Therapeutics (Hong Kong) Limited studies most, compare against other sponsors active in the same condition before evaluating a specific study. See mCRPC (Metastatic Castration-resistant Prostate Cancer) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Acerand Therapeutics (Hong Kong) Limited pipeline card: 1 registered trials from official public datasets.Report a data error.